REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
FDA Approves First Drug to Treat Dementia-Associated Agitation in
A first: FDA approves drug to treat agitation in Alzheimer's
FDA Accepts sNDA for Rexulti for Alzheimer's Agitation
Otsuka and Lundbeck Issue Statement on FDA Advisory Committee
Rexulti Works for Agitation in Alzheimer's, Despite Risks, Says
Otsuka and Lundbeck Receive the US FDA's Approval for Rexulti
For Alzheimer's Agitation, Promising News from Rexulti
Pharma News for Sarepta, Astellas, SiSaf, ImmPACT Bio, Otsuka
FDA Approves First Drug for Alzheimer's-Related Agitation Symptoms
FDA approves new drug for Alzheimer's-Associated agitation
FDA Approves First Drug to Treat Agitation Symptoms Associated
Lundbeck, Otsuka secure FDA approval of Rexulti for Alzheimer's
de
por adulto (o preço varia de acordo com o tamanho do grupo)
